LENZ Therapeutics
LENZ
145 hedge funds and large institutions have $197M invested in LENZ Therapeutics in 2026 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 59 increasing their positions, 34 reducing their positions, and 27 closing their positions.
74% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 34
36% more capital inflows, than outflows
Capital inflows: $40.5M | Capital outflows: $29.8M
4.8% more ownership
Funds ownership: 105.69% → 110.49% (+4.8%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 27
1% less funds holding
Funds holding: 146 → 145 (-1)
28% less call options, than puts
Call options by funds: $874K | Put options by funds: $1.22M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.15M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$3.89M |
| 3 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$3.16M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.93M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$2.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$10.1M |
| 2 |
Silvercrest Asset Management
New York
|
-$2.59M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$2.35M |
| 4 |
Two Sigma Investments
New York
|
-$1.74M |
| 5 |
Morgan Stanley
New York
|
-$1.42M |
LENZ Hedge Fund Activity: Q2 2026 in Review
145 of the 8,352 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q2 2026, worth a combined $197M — down 35% from $303M a quarter earlier.
Fund positioning in LENZ was balanced in Q2 2026: 27 funds opened new positions, 27 closed out, 59 added to existing stakes and 34 trimmed.
The largest buyer was Millennium Management, adding an estimated $5.15M. The largest seller was Franklin Resources, exiting entirely with an estimated $10.1M sold.
- 145 institutional investors held LENZ Therapeutics (LENZ) as of Q2 2026, down from 146 in Q1 2026.
- Funds reported $197M of LENZ Therapeutics stock for Q2 2026, down 35% quarter-over-quarter.
- 27 funds opened new LENZ Therapeutics positions in Q2 2026 and 27 closed out, a net change of 0 holders.
- The largest LENZ Therapeutics buyer in Q2 2026 was Millennium Management, an estimated $5.15M added.
- The largest LENZ Therapeutics seller in Q2 2026 was Franklin Resources, an estimated $10.1M sold.
Based on aggregated 13F filings for Q2 2026.